Economic evaluation of cholesterol-lowering therapy for hypercholesterolemia, cost-effectiveness of HMG-CoA reductase inhibitors

Japanese Pharmacology and Therapeutics

Volumn 27, Issue 4, 1999, Pages 247-258

  Katayama, Takafumi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; HUMAN; HYPERCHOLESTEROLEMIA;

EID: 0032799835     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Medicina 32: 682-683, 1995
2. Goldman L et al: Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 265: 1145-1151, 1991
3. Hay JW et al: An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol 67: 789-796, 1991
4. Martens LL et al: Cost effectiveness of cholesterol-lowering therapy in the Netherlands; Simvastatin versus cholestyramine. Am J Med 87: 54S-58S, 1989
5. Glick H et al: A model for evaluating the cost-effectiveness of cholesterol-lowering treatment. Int J Technol Assess Health Care 8: 719-734, 1992
6. Peter C, Bruce MP: The association between cholesterol and death from injury. Ann Intern Med 120: 848-855, 1994
7. Shepherd J et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301-1307, 1995
8. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease; The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389, 1994
9. Medical Practice 10: 2425-2428, 1993
10. Gold MR et al: Cost-effectiveness in Health and Medicine. Oxford Univ Press, NY, 1996
11. Drummond MF et al: Methods for the Economic Evaluation of Health Care Programmes. Oxford Univ Press, Oxford, 1987 ( 1990)
12. Medicina 32: 721-726, 1995
13. Medicina 32: 753-755, 1995
14. Carnett WR: A review of current clinical findings with fluvastatin. Am J Cardiol 78: 20-25, 1996
15. Banga JD et al: Long-term treatment of hypercholesterolemia with fluvastatin: Aa 52-week multicenter safety and efficacy study. Am J Med 96 (6A): 87S-93S, 1994
16. Anderson KM et al: Cardiovascular disease risk profiles. Am Heart J 121: 293-298, 1991
17. Anderson KM et al: An updated coronary risk profile; A statement for health professionals. Circulation 83: 356-362, 1991
18. Hosoda S et al: Long-term follow-up of medically treated patients with coronary artery disease, II; Unstable angina pectoris, asymptomatic periods, and sudden unexpected cardiac events, Jpn Circ J 54: 241-248, 1990
19. Kambara H et al (KYSMI): Long-term prognosis after myocardial infarction; Univariate and multivariate analysis of clinical characteristics in 1000 patients. Clin Cardiol 16: 872-878, 1993
20. Kambara H et al (KYSMI): Gender difference in long-term prognosis after myocardial infarction; Clinical characteristics in 1000 patients. Jpn Circ J 59: 1-10, 1995
21. Laird NM, Mosteller F: Some statistical methods for combining experimental results. Int J Technol Assess Health Care 6: 5-30, 1990
22. Kinosian BP, Eisenberg JM: Cutting into cholesterol; Cost-effective alternatives for treating hypercholesterolemia. JAMA 259: 2249-2254, 1988
23. Gamerman D: Markov Chain Monte Carlo, Text in Statistical Science Series. Chapman & Hall, 1997
24. Fuchs VR: The Health Economy. Harvard Univ Press, 1986
25. Drummond MF: Guidelines for pharmacoeconomic studies, the way forward. Pharmacoeconomics 6: 493-497, 1994
26. Australian Commonwealth, Department of Health, Housing and Community Services: Guidelines for the pharmaceutical industry on preparation of submission to the pharmaceutical benefits advisory committee. Commonwealth Department, 1992
27. Ontario Ministry of Health: Ontario guidelines for economic analysis of pharmaceutical products. Ontario Ministry of Health, 1994
28. Tompson D, Oster G: Cost-effectiveness of drug therapy for hypercholesterolemia. Pharmacoeconomics 2: 34-42, 1992
29. Laupacis A et al: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 146: 473-481, 1992
30. Cagguila AW et al: Cholesterol-lowering intervention program; Effect of the step I diet in community office practices. Arch Intern Med 156: 1205-1213, 1996
31. Plans PP: Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain. Public Health 111: 33-40, 1997
32. Field K et al: Strategies for reducing coronary risk factors in primary care; Which is most cost effective? Br Med J 310: 1109-1112, 1995
33. Muldoon MF et al: Lowering cholesterol concentrations and mortality; A quantitative review of primary prevention trials. Br Med J 301: 309-314, 1990